2017 American Transplant Congress
No Impact of One Year of Everolimus, as Compared to MPA, in the Reversal of Left Ventricular Hypertrophy in Elderly Renal Transplant Recipients – Preliminary Data from Then Everold Study.
It has been suggested that mTor inhibitors may contribute to the reversal of myocardial hypertrophy after transplantation possibly due to its biological effects like enhanced…2017 American Transplant Congress
Personalizing Immunosuppression with Molecular Phenotyping in Pediatric Liver Transplantation.
Pediatric Abdominal Transplant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Background: Optimizing immunosuppression requires selecting an agent which can inhibit the dominant anti-rejection mechanism in individual children with liver transplantation (LTx). Extended use of steroids,…2017 American Transplant Congress
Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
Background: Chronic antibody mediated rejection (cAMR) is a major cause of long-term kidney transplant (KT) loss. Antibody or immune cell depletional therapies have unclear efficacy…2017 American Transplant Congress
Long-Term Outcomes After Liver Transplantation (tx) with Everolimus (EVR) and Mycophenolic Acid (MPA) in a Calcineurin Inhibitor-Free Regimen: The CERTITUDE Trial.
Background. Long-term outcomes under EVR with MPA and no calcineurin inhibitor are undocumented after liver tx.Methods. CERTITUDE is a prospective, multicenter, observational study of liver…2017 American Transplant Congress
Immunosuppressive Treatment Alters Gut Microbiota and Modified Gut Microbiota Affects Immune Status.
Department of Urology, Beijing Chaoyang Hospital, CCMU, Beijing, China
Objectives: Immunosuppressive therapies could change the host-microbial interactions, especially gut microbiota, which is an important component in systemic immunity. We evaluated the relationship between immunosuppression…2017 American Transplant Congress
Evaluating T Cell Repopulation Post Alemtuzumab Induction with a Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC
We reported that alemtuzumab induction followed by belatacept-sirolimus based immunosuppression effectively prevents costimulation blockade resistant rejection (CoBRR). This study investigates the phenotypic characteristics of repopulating…2017 American Transplant Congress
Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy.
Department of Surgery, Samsung Medical Center, Seoul, Korea
PurposeIgA nephropathy (IgAN) may recur after kidney transplantation (KT) and potentially jeopardize the survival of the graft. The object of this study was to analyze…2017 American Transplant Congress
Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton's Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Preformed and de novo donor specific antibodies (DSA) contribute significantly to demise of allograft functions. There is no approved therapies for prevention or treatment…2017 American Transplant Congress
CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells Facilitate Prolongation of Graft Survival in Old Recipient Mice Treated with Rapamycin.
Although the elderly represent a rapidly growing population among transplant recipients, age-specific aspects have not been considered sufficiently in clinical trials. Moreover, age-specific effects of…2017 American Transplant Congress
Personalized Tacrolimus (TAC) Dosing Using Genetic Variants in Caucasian Kidney Transplant (Tx) Recipients.
TAC is an immune suppressant with a narrow therapeutic index and high pharmacokinetic (PK) variability leading to uncertainty in blood concentrations. We previously developed an…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 138
- Next Page »